

Trust Board

Report Cover Sheet

Agenda Item: 10

Date of Meeting:	Wednesday 29 th July 2020			
Report Title:	Consolidated Finance Report			
Purpose of Report:	To provide a summary of performance as at 30 th June 2020 (Month 3) for the Group (inclusive of Trust and QE Facilities, excluding Charitable Funds).			
	Decision: <input type="checkbox"/>	Discussion: <input type="checkbox"/>	Assurance: <input checked="" type="checkbox"/>	Information: <input type="checkbox"/>
Corporate Objectives report relates to: (Including reference to any specific risk)	9. Meet the Trust's financial requirements, hitting our control total by reducing costs and improving efficiency 10. Ensure the Trust continues to be well-led and has a clear strategy for the future			
Recommendations: (Action required by Board of Directors)	The Board is asked to note the reported financial performance for Month 3 2020/21.			
Financial Implications:	As included in the report			
Risk Management Implications:	As included in the report			
Human Resource Implications:	None			
Equality and Diversity Implications:	Objective 3 Leaders within the Trust are informed and knowledgeable about the impact of business decisions on a diverse workforce and the differing needs of the communities we serve.			
Author:	Mrs Kris Mackenzie, Deputy Director of Finance			
Presented by:	Mrs Jacqueline Bilcliff, Group Director of Finance			

Executive Summary

The purpose of this report is to inform the Board of Directors of the financial and contract performance position of the Group for the period to 30th June 2020.

Summary

In response to the Covid 19 outbreak, guidance was issued in March 2020 that suspended the 2020/21 national operational planning process. An interim financial framework was established intended initially to cover the period 1 April to 31 July 2020.

During the period 1 April to 31 July, the Trust will receive a guaranteed level of income that is intended to reflect the actual cost base. Therefore, it is a national expectation that sufficient funds will be provided to enable the Trust to return an overall income and expenditure break even position for these four months.

The cash payment profile has been amended so that the Trust will receive cash payments in advance, delivering a positive cash flow for this period.

In response, the Trust has suspended its internal financial control framework and in this paper reports against the projected break even position for the period of the national interim financial framework. A national formula has re-set the planned income and expenditure levels for this period, and so when this paper reports performance against plan, it is in reference to the revised plan issued by NHSI/E.

Recommendation

The Board are asked to note the financial position and financial performance for month 3 of 2020/21 and the key assumptions made

Key financial performance indicators

Finance KPIs	Plan	Actual	Difference
Performance against control total (including PSF & Top ups)	0	0	0
Performance against control total (excluding PSF & Top ups)	(8,099)	(10,403)	(2,304)
Capital spend	633	801	168
Cash position	4,519	21,191	16,672
Liquidity days	(17.51)	(8.05)	(9.46)

Key financial metrics

Not reported under the interim financial framework.

Key risks

Risk	CRR	Progress Note
Failure to deliver efficiency schemes	20	National interim financial framework has minimised the requirement for efficiencies during the outbreak, but there is a risk that remains for the response and recovery phase and return to 'normal' financial responsibilities.
Divisional overspend against control totals	16	Response to Covid 19 outbreak has meant that costs have been fluid across the organisation. For example, substantive staff have worked where required and not been retained within divisions.
Provider sustainability funding	12	PSF currently suspended as part of the interim financial framework.
Insufficient funding for capital schemes	12	£1.4m of Covid 19 capital spend - will impact on capital programme if not fully reimbursed.
Group liquidity	12	Interim financial framework has ensured prompt and advance inflow of cash, with associated modelling identifying sufficient cash balances for the remainder of the financial year, with no dependency upon borrowing.

Section 1 - Summary Income and Expenditure Position (see Appendix 1)

As at 30th June the Group is reporting a deficit position (excluding Top-Up) of **£10.402m** for the period. This is against a revised planned deficit of **£8.099m**, an adverse variance of **£2.303m**. Once Top-Up funding is incorporated, the Group reports a breakeven position, as projected by the NHSE/I covid regime.

Within this total operating income (including Top-Up funding) is more than the revised plan by **£1.403m**, total operating expenses are more than the revised plan by **£1.250m** and other non-operating expenses are more than the revised plan by **£0.209m**. Adjusting for the impact of donated assets this gives a breakeven position.

An expanded Income & Expenditure performance is presented at **Tables 1 and 2**.

Section 2 - Income Analysis (see Appendix 1 Table 2)

The reported income position as at June is an over recovery against revised plan of **£1.403m**. This comprises an over recovery of **£0.009m** for operating income from patient care activities and **£1.394m** against other operating income.

As part of the interim financial framework, activity based billing has been postponed with the exception of inter-trust invoicing, and has been replaced by a block value for NHS income.

The block values were calculated centrally based on the income the Trust received during December 2019; with an inflation uplift of 2.8% applied. Using the average expenditure of the months November 2019, December 2019 and January 2020 to derive anticipated costs, it was recognised nationally that this initial block funding would not bring the Trust back to break-even (a requirement of the interim financial framework), therefore a further payment of non-recurrent income known as 'Top-Up' was allocated. Furthermore, there is an avenue to apply for additional retrospective 'Top-Up' funding where necessary if there are reasonable costs incurred in response to the Covid-19 outbreak.

Operating income from patient care activities is an over recovery of **£0.009m**, therefore is considered break-even. This comprises of an under achievement from CCG Commissioners totalling **£0.023m**, an over performance against control total against NHS England Commissioners of **£0.087m**, an over performance against Foundation Trust Income of **£0.167m** and an underperformance against other Income for patient care activities totalling **£0.224m**.

Other operating income is an over recovery of **£1.394m**, with an adverse **£0.910m** relating to lost non-patient care income that sits outside of the block values identified as part of the interim financial framework. The favourable balance is **£2.303m** of additional income that relates to further retrospective funding that the Trust has sought over and above the block value and the Top-Up value resulting from costs incurred in response to the Covid 19 outbreak.

Section 3 - Expenditure Analysis (see Appendix 1 and 2)

As at June operating expenses are higher than plan by **£1.250m**, comprising of a pay underspend of **£0.767m** and a non-pay overspend of **£1.869m** with depreciation and revaluation overspends of **£0.148m**. See **Tables 1 and 2**.

Tables 3, 4, 5, and 6 highlight the different pressures within the overspending employee position and the run rate for the component parts of the employee budgets; substantive staff, waiting list payments, agency and contract staff and bank. **Tables 7 and 8** present the same for non-pay.

As part of the interim financial framework, the Trust is required to diligently record all expenditure incurred in response to the Covid 19 outbreak. As at June 2020 the Trust has incurred cost of **£9.163m**, with further detail provided in **Table 9**. Additional staffing costs incurred including bank and agency across all staffing groups has cost **£2.386m** and the non-staff element of **£6.777m** includes expenditure on behalf of Newcastle Gateshead CCG and costs of laboratory reagents and equipment, computer hardware, decontamination and clinical supplies.

Section 4 - CRP performance

The interim financial framework has set allocated funding on the assumption that no efficiencies will be delivered for the period 1 April to 31 July 2020. The Trust is pursuing its internal financial framework for the remainder of the financial year and efficiencies are a key part of its delivery. Therefore, there is ongoing work within the organisation in response to this.

Section 5 - Cash and working balances (see Appendix 3)

Cash at the beginning of the 2020/2021 financial year was £5.800m above initial plan, at £14.400m, due in the main to scheduled creditor payments in respect of the 2019/2020 financial year end. The cash position was further strengthened by the receipt of an additional £4.700m of PSF/FRF monies in respect of 2019/2020. The cash position presented has been adjusted for payments in advance, with June's Statement of Financial Position inclusive of July's contract income. Current contract arrangements and reduced elective activity in the hospital has also had a positive impact upon cash levels, however this is not expected to be maintained for the remainder of the financial year as revised arrangements are anticipated.

The adjusted cash position of £21.191m as at 30th June is equivalent to 26.26 days operating costs (24.40 days in May) and represents a £1.499m increase from May. Cash is £16.672m above initial plan.

The liquidity metric has declined by 0.55 days against May to -8.05 days however it is 9.46 days better than initial plan, driven by a £6.8m improvement in the working capital balance.

Debtors have reduced by £5.290m in the year due in the main to the receipt of PSF/FRF monies and are £0.691m below initial plan.

Trade and other payables have increased by £1.100m since 31st March 2020 and are cumulatively £8.740m above initial plan. Trade creditors have increased by £1.400m in the year, at £4.100m as at 30th June, however this is a reduction of £0.190m against May. Of the trade creditor balance there are no creditors currently authorised for payment and outstanding over 30 days.

Section 6 – Capital spend (see Appendix 4)

The 2019/2020 capital programme was initially set at £7.090m at the planning stage; this CDEL limit has increased to £7.116m to reflect additional capital funding received of £0.026m in respect of Breast Screening Trailers.

Out with the Trusts CDEL limit, capital expenditure is being incurred in response to the Covid 19 outbreak. Building works have been commissioned on two major schemes, the Tranwell Unit (£0.450m) and Ward 21 (£0.480m). Alongside this, equipment costs of £0.495m have been incurred. Funding in respect of all Covid 19 related capital expenditure has been sought, and approval is anticipated by the end of July and August depending on when claims were submitted. No reimbursement has been received to date, and therefore, the Trust has a risk of over commitment against its CDEL.

The outline of the programme (excluding Covid 19 related expenditure) is included at **Table 11** together with spend to date.

Section 7 – Summary

The Trusts financial position is break even in line with the revised plan introduced as part of the national interim financial framework.

Jacqueline Bilcliff, Group Director of Finance

Appendix 1 – Summary Income and Expenditure Position

Table 1 – summary financial position

STATEMENT OF COMPREHENSIVE INCOME JUNE 2020/21

	GROUP POSITION NHSI/E Covid Plan			VARIANCE	
	Apr- Jul Covid Plan Total	Covid Plan to Date	Actual to Date	Variance (Actual - Budget)	Previous Month Variance
	£000's	£000's	£000's	£000's	£000's
Red >100k over					
Amber <= (£50k) - £99.99k					
Green < (£50.1k)					
Operating					
Operating Income from Patient Care activities					
Total Operating Income From Patient Care activities	(85,624.0)	(64,218.0)	(64,227.0)	(9.0)	(5,392.6)
Total Other Operating Income	(17,900.0)	(13,439.0)	(14,833.3)	(1,394.3)	2,779.0
Total Operating Income	(103,524.0)	(77,657.0)	(79,060.4)	(1,403.4)	(2,613.6)
Total Employee Expenses	67,888.0	50,916.0	50,148.8	(767.2)	(782.7)
Operating Expenses included in EBITDA	100,344.0	75,272.0	76,374.0	1,102.0	2,504.5
Operating Expenses excluded from EBITDA	2,016.0	1,512.0	1,660.3	148.3	80.1
Total Operating Expenses	102,360.0	76,784.0	78,034.4	1,250.4	2,584.5
(Profit)/Loss from Operations	(1,164.0)	(873.0)	(1,026.0)	↑ (153.0)	(29.0)
Non Operating					
Total Non-Operating Income	(56.0)	(42.0)	(9.1)	32.9	19.2
Total Non-Operating Expenses	1,036.0	777.0	918.5	141.5	23.8
(Surplus) / Deficit Before Tax	(184.0)	(138.0)	(116.6)	21.4	13.9
Corporation Tax	184.0	138.0	172.6	⇒ 34.6	23.0
(Surplus) / Deficit After Tax	-	-	55.9	55.9	37.0
(Surplus) / Deficit After Tax from Continuing Operations	-	-	55.9	⇒ 55.9	37.0
Remove capital donations / grants I&E impact	-	-	(56.2)	↑ (56.2)	(37.4)
Other Control Total adjustment	-	-	-	-	-
Impairment	-	-	-	-	-
Adjusted Financial Performance (Surplus) / Deficit	-	-	(0.2)	(0.2)	(0.5)
Adjusted Financial Performance (Surplus) / Deficit	-	-	(0.2)	⇒ (0.2)	(0.5)
Top Up Adjustment	10,780.0	8,099.0	10,402.0	2,303.0	3,110.0
Adjusted Financial Performance (Surplus) / Deficit excluding Top Up	10,780.0	8,099.0	10,401.8	↓ 2,302.8	(1,558.1)

Table 2 – Detailed financial position

STATEMENT OF COMPREHENSIVE INCOME JUNE 2020/21					
	GROUP POSITION NHS/E Covid Plan			VARIANCE	
Red >100k over	Apr- Jul Covid Plan Total	Covid Plan to Date	Actual to Date	Variance (Actual - Budget)	Previous Month Variance
Amber <= (£50k) - £99.99k	£000's	£000's	£000's	£000's	£000's
Green < (£50.1k)					
Operating					
Operating Income from Patient Care activities					
Income From NHS Care Contracts	(85,032.0)	(63,774.0)	(64,006.7)	↑ (232.7)	(5,567.5)
Income From Local Authority Care Contracts	(36.0)	(27.0)	(22.5)	⇒ 4.5	3.0
Private Patient Revenue	(244.0)	(183.0)	(64.0)	↓ 119.0	83.0
Injury Cost Recovery	(308.0)	(231.0)	(53.0)	↓ 178.0	135.5
Other non-NHS clinical revenue	(4.0)	(3.0)	(80.8)	↑ (77.8)	(46.7)
Total Operating Income From Patient Care activities	(85,624.0)	(64,218.0)	(64,227.0)	(9.0)	(5,392.6)
Other Operating Income					
Education and Training Income	(2,308.0)	(1,731.0)	(1,740.3)	⇒ (9.3)	(8.0)
R&D Income	(324.0)	(243.0)	(148.9)	⇒ 94.1	64.5
Top-up Income	(10,780.0)	(8,099.0)	(10,402.0)	↑ (2,303.0)	2,289.0
Other Income	(4,488.0)	(3,366.0)	(2,542.1)	↓ 823.9	433.6
Donations & Grants Received	-	-	-	⇒ -	-
Total Other Operating Income	(17,900.0)	(13,439.0)	(14,833.3)	(1,394.3)	2,779.0
Total Operating Income	(103,524.0)	(77,657.0)	(79,060.4)	(1,403.4)	(2,613.6)
Operating Expenses					
Employee Expenses - Substantive	64,040.0	48,030.0	47,331.8	↑ (698.2)	(819.4)
Employee Expenses - Bank	2,252.0	1,689.0	1,947.4	↓ 258.4	190.6
Employee Expenses - Agency	1,360.0	1,020.0	650.1	↑ (369.9)	(194.5)
Employee Expenses - Other	236.0	177.0	219.5	⇒ 42.5	40.5
Total Employee Expenses	67,888.0	50,916.0	50,148.8	(767.2)	(782.7)
Purchase of Healthcare - NHS bodeis	1,752.0	1,314.0	1,305.3	⇒ (8.7)	49.3
Purchase of Healthcare - Non NHS bodies	476.0	357.0	253.4	↑ (103.6)	(75.3)
NED's	60.0	45.0	45.2	⇒ 0.2	0.1
Supplies & Services - Clinical	11,280.0	8,474.0	5,435.5	↑ (3,038.5)	(2,277.5)
Supplies & Services - General	736.0	552.0	536.7	⇒ (15.3)	10.5
Drugs	5,832.0	4,374.0	3,660.6	↑ (713.4)	(469.6)
Research & Development expenses	48.0	36.0	-	⇒ (36.0)	(24.0)
Education & Training expenses	248.0	186.0	620.2	↓ 434.2	297.3
Consultancy costs	8.0	6.0	7.5	⇒ 1.5	6.0
Establishment expenses	1,244.0	933.0	643.3	↑ (289.7)	(212.4)
Premises	5,268.0	3,951.0	4,107.4	↓ 156.4	32.0
Transport	500.0	375.0	164.0	↑ (211.0)	(101.3)
Clinical Negligence	2,236.0	1,677.0	1,848.0	↓ 171.0	114.0
Operating Leases	-	-	-	⇒ -	-
Other Operating expenses	2,768.0	2,076.0	7,598.3	↓ 5,522.3	5,938.1
Cost Improvement Programme	-	-	-	⇒ -	-
Reserves	-	-	-	⇒ -	-
Operating Expenses included in EBITDA	100,344.0	75,272.0	76,374.0	1,102.0	2,504.5
Depreciation & Amortisation - Purchased / Constructed	2,016.0	1,512.0	1,604.1	⇒ 92.1	67.7
Depreciation & Amortisation - Donated / Granted	-	-	56.2	⇒ 56.2	37.4
Depreciation & Amortisation - Finance Leases	-	-	-	⇒ -	-
Impairment & Revaluation	-	-	0.0	⇒ 0.0	(25.1)
Restructuring Costs	-	-	-	⇒ -	-
Operating Expenses excluded from EBITDA	2,016.0	1,512.0	1,660.3	148.3	80.1
Total Operating Expenses	102,360.0	76,784.0	78,034.4	1,250.4	2,584.5
(Profit)/Loss from Operations	(1,164.0)	(873.0)	(1,026.0)	↑ (153.0)	(29.0)
Non Operating					
Non-Operating Income					
Finance Income	(56.0)	(42.0)	(9.1)	⇒ 32.9	19.2
Total Non-Operating Income	(56.0)	(42.0)	(9.1)	32.9	19.2
Non-Operating Expenses					
Finance Costs	212.0	159.0	198.6	⇒ 39.6	27.2
Gains / (Losses) on Disposal of Assests	-	-	-	⇒ -	-
PDC dividend expense	824.0	618.0	719.9	↓ 101.9	(3.4)
Total Finance Costs (for non-financial activities)	1,036.0	777.0	918.5	141.5	23.8
Other Non-Operating Expenses					
Misc. Other Non-Operating expenses	-	-	-	⇒ -	-
Total Non-Operating Expenses	1,036.0	777.0	918.5	141.5	23.8
(Surplus) / Deficit Before Tax	(184.0)	(138.0)	(116.6)	21.4	13.9
Corporation Tax	184.0	138.0	172.6	⇒ 34.6	23.0
(Surplus) / Deficit After Tax	-	-	55.9	55.9	37.0
(Surplus) / Deficit After Tax from Continuing Operations	-	-	55.9	55.9	37.0
Remove capital donations / grants I&E impact	-	-	(56.2)	↑ (56.2)	(37.4)
Other Control Total adjustment	-	-	-	⇒ -	-
Impairment	-	-	-	⇒ -	-
Adjusted Financial Performance (Surplus) / Deficit	-	-	(0.2)	(0.2)	(0.5)
Adjusted Financial Performance (Surplus) / Deficit	-	-	(0.2)	(0.2)	(0.5)
Top Up Adjustment	10,780.0	8,099.0	10,402.0	2,303.0	3,110.0
Adjusted Financial Performance (Surplus) / Deficit excluding top Up	10,780.0	8,099.0	10,401.8	↓ 2,302.8	(1,558.1)

Appendix 2 – Expenditure analysis

Table 3 – Budgeted pay expenditure

STATEMENT OF COMPREHENSIVE INCOME JUNE 2020/21

Red >100k over Amber <= (£50k) - £99.99k Green < (£50.1k)	GROUP POSITION NHS/E Covid Plan			VARIANCE	
	Apr- Jul Covid Plan Total	Covid Plan to Date	Actual to Date	Variance (Actual - Budget)	Previous Month Variance
	£000's	£000's	£000's	£000's	£000's
Operating Expenses					
Employee Expenses - Substantive	64,040.0	48,030.0	47,331.8	↑ (698.2)	(819.4)
Employee Expenses - Bank	2,252.0	1,689.0	1,947.4	↓ 258.4	190.6
Employee Expenses - Agency	1,360.0	1,020.0	650.1	↑ (369.9)	(194.5)
Employee Expenses - Other	236.0	177.0	219.5	→ 42.5	40.5
Total Employee Expenses	67,888.0	50,916.0	50,148.8	(767.2)	(782.7)

Agency Position	
Jun-21	Variance from Ceiling
Month of	↑ (75,468)
YTD	↑ (99,936)

*note Agency ceiling based on draft plan submitted to NHSE/I

Table 4 – Substantive pay run rate (including WLIs)




Table 5 – Non substantive pay run rate




Table 6 – Whole Time Equivalent run rate




Table 7 – Budgeted non pay expenditure

STATEMENT OF COMPREHENSIVE INCOME
JUNE 2020/21

	GROUP POSITION NHS/E Covid Plan			VARIANCE	
	Apr- Jul Covid Plan Total	Covid Plan to Date	Actual to Date	Variance (Actual - Budget)	Previous Month Variance
	£000's	£000's	£000's	£000's	£000's
Red >100k over					
Amber <= (£50k) - £99.99k					
Green < (£50.1k)					
Purchase of Healthcare - NHS bodeis	1,752.0	1,314.0	1,305.3	➡ (8.7)	49.3
Purchase of Healthcare - Non NHS bodies	476.0	357.0	253.4	⬆ (103.6)	(75.3)
NED's	60.0	45.0	45.2	➡ 0.2	0.1
Supplies & Services - Clinical	11,280.0	8,474.0	5,435.5	⬆ (3,038.5)	(2,277.5)
Supplies & Services - General	736.0	552.0	536.7	➡ (15.3)	10.5
Drugs	5,832.0	4,374.0	3,660.6	⬆ (713.4)	(469.6)
Research & Development expenses	48.0	36.0	-	➡ (36.0)	(24.0)
Education & Training expenses	248.0	186.0	620.2	⬆ 434.2	297.3
Consultancy costs	8.0	6.0	7.5	➡ 1.5	6.0
Establishment expenses	1,244.0	933.0	643.3	⬆ (289.7)	(212.4)
Premises	5,268.0	3,951.0	4,107.4	⬆ 156.4	32.0
Transport	500.0	375.0	164.0	⬆ (211.0)	(101.3)
Clinical Negligence	2,236.0	1,677.0	1,848.0	⬆ 171.0	114.0
Operating Leases	-	-	-	➡ -	-
Other Operating expenses	2,768.0	2,076.0	7,598.3	⬆ 5,522.3	5,938.1
Cost Improvement Programme	-	-	-	➡ -	-
Reserves	-	-	-	➡ -	-
Non Pay Operating Expenses included in EBITDA	32,456.0	24,356.0	26,225.3	1,869.3	3,287.2

Table 8 – Non Pay Run rate




Table 9 – Covid 19 spend

Covid Spend Group position		
Type	Subjective Plan	Total £'000's
Staff	Substantive Staff	1,639.4
	Bank Staff	587.7
	Agency / Contract	158.5
Staff Total		2,385.6
Non Staff	Other	5,451.5
	Supplies and Services – Clinical (Excluding Drugs Costs)	591.5
	Premises - Other	539.2
	Establishment	88.7
	Supplies and Services - General	81.7
	Purchase Of Healthcare From NHS Bodies	14.0
	Drugs Costs (Drug Inventory Consumed and Purchase Of Non-Inventory Drugs)	11.6
	Education and Training - Non-Staff	.0
	Transport	(1.5)
Non Staff Total		6,776.9
Grand Total		9,162.6

Appendix 3 – Cash and working balances

Table 10 – statement of financial position

Statement of Position - June 2020

	2020/2021	2020/2021		2020/2021	2020/2021
	May 2020 Group	June 2020 Group	Variance - Prior Month	June 2020 QEF	May 2020 FT
	£000's	£000's	£000's	£000's	£000's
Assets					
<u>Non-Current Assets</u>					
Investments	80	80	0	80	16,824
Property, Plant and Equipment, Net	115,947	116,053	107	407	115,646
Trade and Other Receivables, Net	2,174	2,314	140	889	1,425
Finance Lease - Intragroup				43,416	0
Trade and Other Receivables - Intragroup Loan	0	0	0		19,771
Total Non Current Assets	118,201	118,447	247	44,793	153,666
<u>Current Assets</u>					
Inventories	4,276	4,305	30	2,246	2,060
Trade and Other Receivables - NHS	7,373	6,138	(1,236)	561	5,577
Trade and Other Receivables - Non NHS	5,141	3,981	(1,160)	626	3,355
Trade and Other Receivables - Intragroup	5,703	5,644	(59)	5,426	218
Trade and Other Receivables - Other	0	0	0		0
Prepayments	4,398	4,343	(55)	441	3,901
Cash and Cash Equivalents	43,070	44,022	952	7,512	36,510
Other Financial Assets - PDC Dividend	1,421	1,506	85	561	945
Accrued Income	303	224	(80)		224
Finance Lease - Intragroup				1,148	0
Trade and Other Receivables - Intragroup Loan					2,898
Total Current Assets	71,685	70,162	(1,523)	18,522	55,686
Liabilities					
<u>Current Liabilities</u>					
Deferred Income	26,207	25,661	(547)	202	25,458
Provisions	781	775	(6)	0	775
Current Tax Payables	3,996	4,073	77	321	3,753
Trade and Other Payables - Intragroup	5,703	5,644	(59)	218	5,426
Trade and Other Payables - NHS	1,643	1,561	(83)	338	1,222
Trade and Other Payables - Other	7,816	7,479	(336)	2,658	4,822
Trade and Other Payables - Capital	456	345	(111)	0	345
Other Financial Liabilities - Accruals	25,515	25,177	(338)	4,868	20,309
Other Financial Liabilities - Borrowings FTFF	1,356	1,177	(179)	0	1,177
Other Financial Liabilities - PDC Dividend	409	720	311	0	720
Other Financial Liabilities - Intragroup Borrowings	0	0	0	2,898	0
Finance Lease - Intragroup	0	0	0	0	1,148
Total Current Liabilities	73,882	72,612	(1,270)	11,503	65,155
NET CURRENT ASSETS (LIABILITIES)	(2,197)	(2,450)	(253)	7,019	(9,469)
<u>Non-Current Liabilities</u>					
Deferred Income	2,647	2,660	13	1,869	791
Provisions	2,717	2,717	0	0	2,717
Trade and Other Payables - Other	0	0	0	0	0
Other Financial Liabilities - Accruals	0	0	0	0	0
Other Financial Liabilities - Intragroup Borrowings	0	0	0	19,771	0
Other Financial Liabilities - Borrowings FTFF	27,423	27,423	0	0	27,423
Finance Lease - Intragroup				0	43,416
Total Non-Current Liabilities	32,787	32,800	13	21,640	74,347
TOTAL ASSETS EMPLOYED	83,216	83,198	(19)	30,172	69,850
Tax Payers' and Others' Equity					
PDC	118,208	118,208	0	0	118,208
Taxpayers Equity	0	0	0	0	0
Share Capital	0	0	0	16,824	0
Retained Earnings (Accumulated Losses)	(44,112)	(44,131)	(19)	13,347	(57,478)
Other Reserves	0	0	0	0	0
Revaluation Reserve	9,022	9,022	0	0	9,022
Misc Reserve	99	99	0	0	99
TOTAL TAXPAYERS EQUITY	83,217	83,198	(19)	30,172	69,850
TOTAL ASSETS EMPLOYED	83,217	83,198	(19)	30,172	69,850

Appendix 4 – Capital programme delivery

Table 11 – detailed capital schemes

Scheme description	2020/21 Plan £000	Plan to month 3 £000	Actual to month 3 £000
IT GDE	2,350	165	233
IT Radiology	181	181	0
IT Breast Screening	250	0	0
IT Community Mobile Working	50	10	0
ECC Cladding	360	0	0
Equipment Replacement	1,189	190	382
Maternity Scheme	1,100	30	36
Paediatric Scheme	600	0	0
Backlog Maintenance	396	31	134
H&S Disabled Access	100	15	11
Simulation Training Equipment	80	0	0
Salix Energy Conservation	50	0	5
Dementia Environmental	47	0	0
HPV	30	0	0
Woodside	27	0	0
CQC Ambulance Works	24	0	0
Gynea. Equipment	15	0	0
Workforce Dept. Refurbishment	11	11	0
Donated Assets	230	0	0
	7,090	633	801